-
Uncategorized2 months ago
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and...
-
Uncategorized2 months ago
Bristol Myers reaches a crossroads as a make-or-break year takes shape
Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most...
-
Uncategorized2 months ago
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for...
-
Uncategorized2 months ago
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including...
-
Uncategorized2 months agoMeet the Researcher: Fred Ramsdell, Nobel winner
Fred Ramsdell is Founder and Advisor, Sonoma Biotherapeutics and one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T...
-
Uncategorized2 months ago
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month...
-
Uncategorized2 months ago
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside of the country.
-
Uncategorized2 months ago
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the...
-
Uncategorized2 months agoA patent win for Pfizer and BridgeBio
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several biotech leaders...
-
Uncategorized2 months ago
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
